{"name":"ShenZhen Cell Valley","slug":"shenzhen-cell-valley","ticker":"","exchange":"","domain":"","description":"ShenZhen Cell Valley is a biotechnology company focused on developing innovative cell therapies, particularly in the area of CAR-T treatments for autoimmune diseases. The company is currently conducting Phase 1 clinical trials for its lead product, CD19 CAR-T cells, aimed at treating relapsed/refractory autoimmune conditions.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxOVXVJdGJvcnZLVXRjX3hsaVlYV1dfbDV3RndnM3AxWUtZRTNKR2NEb3dwY1V5V3lILXc4enVsNmdVenFCYUZpS3BLSF9Sb05nb3JVSElLQ3g4anBvWDJuQnFVM2lEY2Q1U2ZtNEs3QU52bENFWU42ZGJMSHMzcVN4RUd2Nm1pc29wNUZ0WlVNdC1hUVhPQkExYnkwVmY5aEtIVzhfNkNYTQ?oc=5","date":"2024-10-23","type":"pipeline","source":"sz.gov.cn","summary":"Biopharmaceutical industry - sz.gov.cn","headline":"Biopharmaceutical industry","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}